Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...
Battles are emerging between tech companies and governments that are trying to limit the harm to children and adolescents ...
FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
Child Sleep Problems? 8 Bedtime Habits That Secretly Disrupt Your Kid’s Growth And Brain Development
Here are the common bedtime habits that may harm your child’s sleep, growth and brain development and know expert tips to ...
In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...
Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...
In this article, we will look at the 12 Best Undervalued Stocks to Invest In Right Now. On March 3, Katie Stockton, Fairlead ...
MedPage Today on MSN
Once-Weekly Treatment Approved for Achondroplasia in Kids
Navepegritide is indicated for those ages 2 and older with open epiphyses ...
She revolutionized women’s sprinting with her speed and flamboyant fashion sense, and was a three-time gold medalist at the ...
MedPage Today on MSN
FDA Expands Sogroya Approval; Record Obesity Rates in Kids; Cushing's and Depression
News and commentary from the endocrinology world ...
Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results